Product
Lumigan
1 clinical trial
2 indications
Indication
Open-angle GlaucomaIndication
ocular hypertensionClinical trial
A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint Comparing Generic Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® (Bimatoprost Ophthalmic Solution) 0.01% in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both EyesStatus: Not yet recruiting, Estimated PCD: 2025-03-01